Effects of L-Phenylalanine Mustard and L-Buthionine Sulfoximine on Murine and Human Hematopoietic Progenitor Cells in Vitro

Cancer Research

Volumn 50, Issue 13, 1990, Pages 4038-4043

  Du, De Lin ^a   Volpe, Donna A ^a   Murphy, Martin J ^a   Grieshaber, Charles K ^b  

^a Hippie Cancer Research Center   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTHIONINE SULFOXIMINE; MELPHALAN;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL CULTURE; DRUG CYTOTOXICITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMAL; BUTHIONINE SULFOXIMINE; COLONY-FORMING UNITS ASSAY; DRUG SYNERGISM; FEMALE; HEMATOPOIETIC STEM CELLS; HUMAN; MELPHALAN; METHIONINE SULFOXIMINE; MICE; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS;

EID: 0025290704     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Cline, M. J., and Haskell, C. M. Drugs used in cancer chemotherapy. In: M. J. Cline and C. M. Haskell (eds.), Cancer Chemotherapy, Ed. 3, p. 39. Philadelphia: W.B. Saunders Co., 1980.
2. Smith, J. P., Rutledge, F., and Warton, J. T. Chemotherapy of ovarian cancer. New approaches to treatment. Cancer (Phila.), 30: 1565–1571, 1975.
3. Somfai-Relle, S., Suzukake, K., Vistca, B. P., and Vistica, D. T. Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard. Biochem. Pharmacol., 33: 485–490, 1984.
4. Green, J. A., Vistica, D. T., Young, R. C., Hamilton, T. C., Rogan, A. M., and Ozols, R. F. Potentiation of Melphalan cytotoxicity in human ovarian cancer cell lines by glutathione deletion. Cancer Res., 44: 5427–5431, 1984.
5. Hamilton, T. C., Winker, M. A., Louie, K. G., Batist, G., Behrens, B. C., Tsuruo, T., Grotzinger, K. R., McKoy, W. M., Young, R. C., and Ozols, R. F. Augmentation of Adriamycin, Melphalan and cisplatin cytotoxicity in drug resistant and sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem. Pharmacol., 34: 2583–2586, 1985.
6. Ozols, R. F., Louie, K. G., Plowman, J., Behrens, B. C., Fine, R. L., Dykes, D., and Hamilton, T. C. Enhanced Melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem. Pharmacol., 36: 147–153, 1987.
7. Hansson, J., Edgren, M., Ehrsson, H., Ringborg, U., and Nilsson, B. Effect of D,L-buthionine-5,/?-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells. Cancer Res., 48: 19–26, 1988.
8. Skapek, S. X., Colvin, O. M., Griffith, O. W., Elion, G. B., Bigner, D. D., and Friedman, H. S. Enhanced Melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice. Cancer Res., 48: 2764–2767; 1988.
9. Friedman, H. S., Colvin, O. M., Griffith, O. W., Lippitz, B., Elion, G. B., Schold, S. C., Jr., Hilton, J., and Bigner, D. D. Increased Melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion. J. Natl. Cancer Inst., 81: 524–527, 1989.
10. Dorr, R. T., Soble, M. J., and Greenberg, B. Effect of glutathione depletion by L-buthionine (S/R) sulfoximine on the toxicity and antitumor efficacy of carmustine (BCNU), cyclophosphamide (CTX), doxorubicin (DOX) and Melphalan (l-PAM), in murine MOPC-315 plasmacytoma. Proc. Am. Assoc. Cancer Res., 27: 374a, 1986.
11. Kramer, R. A., Ahmad, S., and Vistica, D. Toxicologic considerations in chemosensitization of Melphalan (l-PAM) by buthionine sulfoximine (BSO) in mice. Proc. Am. Assoc. Cancer Res., 27: 419a, 1986.
12. Russo, A., Tochner, Z., Phillips, T., Carmichael, J., DeGraft, W., Friedman, N., Fisher, J., and Mitchell, J. B. In vivo modulation of glutathione by buthionine sulfoximine: effect on marrow response to Melphalan. Int. J. Radit. Oncol. Biol. Phys., 12: 1187–1189, 1986.
13. Kramer, R. A., Greene, K., Ahmad, S., and Vistica, D. T. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine. Cancer Res., 47: 1593–1597, 1987.
14. Soble, M. J., and Dorr, R. T. Lack of enhanced myelotoxicity with buthionine sulfoximine and sulfhydryl-dependent anticancer agents in mice. Res. Commun. Chem. Path. Pharmacol., 55: 161–180, 1987.
15. Ali-Osman, F., Giblin, J., Berger, M., Murphy, M. J., Jr., and Rosenblum, M. L. Chemical structure of carbamoylating groups and their relationship to bone marrow toxicity and antiglioma activity of bifunctionally alkylating and carbamoylating nitrosourea. Cancer Res., 45: 4185–4191, 1985.
16. Murphy, M. J., Jr., and Sullivan, M. E. Culture of erythroid stem cells from murine and human marrow and blood. In: M. J. Murphy, Jr. (ed.), In Vitro Aspects of Erythropoiesis, pp. 262–265. New York: Springer-Verlag, 1978.
17. Johnson, G. R., and Metcalf, D. Pure and mixed erythroid colony formation in vitro stimulated by spleen conditioned medium with no detectable erythropoietin. Proc. Natl. Acad. Sei. USA, 74: 3879–3882, 1977.
18. Gallicchio, V. S., and Murphy, M. J., Jr. In vitro erythropoiesis. II. Cyto-chemical enumeration of erythroid stem cells (CFU-e and BFU-e) from normal mouse and human hematopoietic tissues. Exp. Hematol., 7: 219–224, 1979.
19. McLeod, D. L., Shreeve, M. M., and Axelrad, A. A. Improved plasma culture system for production of erythrocytic colonies in vitro: quantitative assay method for CFU-E. Blood, 44: 517–534, 1974.
20. Kuriya, S., Kwak, J., Tajika, K., Minoda, Y., Nomura, T., and Murphy, M. J., Jr. Cloning of murine megakaryocyte progenitor cells in a fibrin clot culture system. Exp. Hematol., 15: 896–901, 1987.
21. Nakeff, A., and Daniel-McQueen, S. In vitro cloning assay for a new class of megakaryocyte precursor: colony forming unit megakaryocyte (CFU-M). Proc. Soc. Exp. Biol. Med., 151: 587–590, 1976.
22. Du, D. L., Volpe, D. A., and Murphy, M. J., Jr. Microcapillary clonogenic assays for human marrow hematopoietic progenitor cells. Int. J. Cell Cloning, 7: 303–313,1989.
23. Burgess, A. W., Wilson, E. M. A., and Metcalf, D. Stimulation by human placental conditioned medium of hematopoietic colony formation by human marrow cells. Blood, 49: 573–583,1977.
24. Dorr, R. T., Liddil, J. D., and Soble, M. J. Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(S7?)-sulfoximine on human and murine tumor cells. Invest. New Drugs, 4: 305–313, 1986.
25. Shrieve, D. C., and Harris, J. W. Effects of glutathione depletion by buthionine sulfoximine on the sensitivity of EMT6/SF cells to chemotherapy agents or X-radiation. Int. J. Radit. Oncol. Biol. Phys., 12: 1171–1174, 1986.
26. Chabner, B. A., and Myers, C. E. Clinical pharmacology of cancer chemotherapy. In: V. T. De Vita, S. Hellman, and S. A. Rosenberg (eds.), Principles and Practice of Oncology, Ed. 2, pp. 317–318. Philadelphia: Lippincott, 1985.
27. Tatterall, M. H., Jarman, M., Newlands, E. S., Holyhead, L., Milstead, R. A., and Weinberg, A. Pharmacokinetics of Melphalan following oral or intravenous administration in patients with malignant disease. Eur. J. Cancer, 14: 507–513, 1978.
28. Alberts, D. S., Chang, S. Y., Chen, H. S., Evans, T. L., and Moon, T. E. Oral Melphalan kinetics. Clin. Pharmacol. Ther., 26: 737–745, 1979.